Document Detail


Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities.
MedLine Citation:
PMID:  18632533     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To retrospectively determine the benchmark incidence of nephrogenic systemic fibrosis (NSF) related to the confirmed use of different gadolinium chelate contrast agents at four U.S. university tertiary care centers. MATERIALS AND METHODS: Institutional review board approval was obtained for this HIPAA-compliant multi-institutional study; the requirement for informed patient consent was waived. Patients who had a diagnosis of NSF between January 2000 and December 2006 were identified at four tertiary care centers with renal transplant and dialysis services. A standard checklist was used to acquire reliable data from the four centers. The diagnosis of NSF was confirmed histopathologically in all patients. The association of NSF development with gadolinium chelate contrast agent administration in each patient was assessed. The type and cumulative dose of contrast agent administered to each patient with NSF were determined at each center by using the standard checklist. The benchmark incidence of NSF was determined and expressed as the ratio of the number of patients with NSF who had undergone gadolinium chelate-enhanced magnetic resonance (MR) imaging, relative to the total number of patients who underwent gadolinium chelate-enhanced MR imaging at each tertiary care center. Benchmark incidences of NSF were compared among the four centers by using Fisher exact tests. RESULTS: Gadodiamide was used at University of North Carolina at Chapel Hill (center A) and Emory University (center B), and gadopentetate dimeglumine was used at Wake Forest University (center C) and Thomas Jefferson University (center D) during the study period. Twenty-three patients at center A, nine patients at center B, three patients at center C, and one patient at center D had NSF and had undergone gadolinium chelate-enhanced MR imaging. The incidence of NSF was one in 2913 patients who underwent gadodiamide-enhanced MR examinations and one in 44,224 patients who underwent gadopentetate dimeglumine-enhanced MR examinations. CONCLUSION: The benchmark incidence of NSF was much greater at the two centers where gadodiamide was used than at the two centers where gadopentetate dimeglumine was used.
Authors:
Rebecca Wertman; Ersan Altun; Diego R Martin; Donald G Mitchell; John R Leyendecker; Ryan B O'Malley; Daniel J Parsons; Edwin R Fuller; Richard C Semelka
Related Documents :
16633213 - Electroconvulsive therapy for treatment of refractory depression in a patient with cyst...
19999223 - Evaluation of diagnostic accuracy of apri for prediction of fibrosis in hepatitis c pat...
12098053 - Male gender: risk factor for severe symptomatic cholelithiasis.
Publication Detail:
Type:  Journal Article; Multicenter Study     Date:  2008-07-15
Journal Detail:
Title:  Radiology     Volume:  248     ISSN:  1527-1315     ISO Abbreviation:  Radiology     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2008-08-19     Completed Date:  2008-09-15     Revised Date:  2009-04-01    
Medline Journal Info:
Nlm Unique ID:  0401260     Medline TA:  Radiology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  799-806     Citation Subset:  AIM; IM    
Copyright Information:
RSNA, 2008
Affiliation:
School of Medicine, University of North Carolina at Chapel Hill, 101 Manning Dr, CB 7510, Chapel Hill, NC 27599-7510, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Academic Medical Centers / statistics & numerical data*
Adolescent
Adult
Aged
Chelating Agents / diagnostic use*
Comorbidity
Gadolinium / diagnostic use*
Humans
Incidence
Magnetic Resonance Imaging / statistics & numerical data*
Middle Aged
Renal Insufficiency / epidemiology*
Risk Assessment / methods*
Risk Factors
Scleroderma, Systemic / epidemiology*
Syndrome
United States / epidemiology
Chemical
Reg. No./Substance:
0/Chelating Agents; 7440-54-2/Gadolinium
Comments/Corrections
Comment In:
Radiology. 2009 Mar;250(3):959; author reply 959-60   [PMID:  19244061 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hepatic malignancies: percutaneous radiofrequency ablation during percutaneous portal or hepatic vei...
Next Document:  Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomiz...